GEN Exclusives

More »

GEN News Highlights

More »
Feb 27, 2012

EC Approves Three-Year Treatment Label Update for Novartis’ Glivec

  • Novartis confirmed that the European Commission approved an update to the Glivec® (imatinib) label to include 36 months of treatment with the drug following surgery for adults with KIT (CD117-positive) gastrointestinal stromal tumors (GIST). FDA approved a similar label update at the start of February in the U.S. where the drug is called Gleevec.

    Regulatory clearance in the EU for the three-year treatment recommendation was based on data from a 397-patient Phase III trial, which showed that recurrence free-survival was 66% for relevant KIT-positive GIST patients receiving Glivec for three years post surgery compared with 48% for patients who received Glivec for just one year. Overall survival rates at five years were 92% and 82%, respectively.

    “This approval marks a key milestone in advancing the postsurgical treatment of GIST for certain patients in Europe, where Glivec is the only available therapy in this setting,” comments Hervé Hoppenot, president of Novartis oncology. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »